Thalys Medical Technology Group Corporation (SHA:603716)
China · Delayed Price · Currency is CNY 15.95
-0.64 (-3.86%)
Nov 2, 2026, 3:00 PM CST
SHA:603716 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 705.5 | 1,073 | 1,806 | 1,992 | 2,293 | 2,590 |
Other Revenue | 3.81 | 3.81 | 5.14 | 14.53 | 16.05 | 9.99 |
| 709.31 | 1,077 | 1,811 | 2,006 | 2,309 | 2,600 | |
Revenue Growth | -43.15% | -40.52% | -9.74% | -13.10% | -11.19% | 22.30% |
Cost of Revenue | 550.25 | 847.07 | 1,482 | 1,616 | 1,860 | 2,057 |
Gross Profit | 159.06 | 229.89 | 328.54 | 389.74 | 448.96 | 542.74 |
Selling, General & Admin | 208.52 | 243.39 | 299.75 | 327.98 | 336.23 | 339.89 |
Research & Development | 34.03 | 41.36 | 46.53 | 43.02 | 29.32 | 35.47 |
Other Operating Expenses | 5.34 | 6.36 | 7.67 | 9.48 | 10.7 | 12.61 |
Operating Expenses | 231.04 | 294.97 | 320.88 | 408.65 | 464.47 | 447.93 |
Operating Income | -71.98 | -65.08 | 7.66 | -18.91 | -15.51 | 94.81 |
Interest Expense | -1.23 | -33.53 | -57.68 | -76.19 | -98.76 | -82.78 |
Interest & Investment Income | 2.83 | 9.06 | 3.84 | 7.51 | 19.36 | 7.95 |
Currency Exchange Gain (Loss) | -0.29 | -0.29 | -0.55 | -3.04 | -7.62 | 0.4 |
Other Non Operating Income (Expenses) | -8.2 | -6.75 | -4.67 | -52.67 | -5.37 | -18.36 |
EBT Excluding Unusual Items | -78.86 | -96.6 | -51.4 | -143.3 | -107.89 | 2.03 |
Impairment of Goodwill | -28.62 | -28.62 | -22.43 | -26.61 | -12.23 | - |
Gain (Loss) on Sale of Investments | -5.51 | -3.45 | -68.01 | -11.3 | -31.8 | -25.66 |
Gain (Loss) on Sale of Assets | -6.26 | -5.43 | -9.37 | -11.83 | -0.02 | 0.4 |
Asset Writedown | -21.64 | -20.74 | - | - | -6.95 | -0.72 |
Other Unusual Items | 2.69 | 2.47 | 2.92 | 0.54 | -32.82 | -0.15 |
Pretax Income | -138.21 | -152.36 | -148.3 | -192.5 | -191.71 | -24.11 |
Income Tax Expense | 44.2 | 49.08 | 45.09 | -35.73 | -1.46 | 14.27 |
Earnings From Continuing Operations | -182.4 | -201.44 | -193.39 | -156.78 | -190.25 | -38.38 |
Minority Interest in Earnings | 6.35 | -5.84 | -15.85 | -1.8 | 36.52 | -11.13 |
Net Income | -176.05 | -207.28 | -209.24 | -158.57 | -153.73 | -49.51 |
Net Income to Common | -176.05 | -207.28 | -209.24 | -158.57 | -153.73 | -49.51 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 217 | 199 | 192 | 193 | 195 | 198 |
Shares Outstanding (Diluted) | 217 | 199 | 192 | 193 | 195 | 198 |
Shares Change | 13.09% | 3.61% | -0.73% | -0.62% | -1.73% | -0.23% |
EPS (Basic) | -0.81 | -1.04 | -1.09 | -0.82 | -0.79 | -0.25 |
EPS (Diluted) | -0.81 | -1.04 | -1.09 | -0.82 | -0.79 | -0.25 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -60.99 | -43.47 | 76.39 | 85.06 | -26.52 | -193.71 |
Free Cash Flow Per Share | -0.28 | -0.22 | 0.40 | 0.44 | -0.14 | -0.98 |
Gross Margin | 22.42% | 21.35% | 18.14% | 19.43% | 19.45% | 20.88% |
Operating Margin | -10.15% | -6.04% | 0.42% | -0.94% | -0.67% | 3.65% |
Profit Margin | -24.82% | -19.25% | -11.56% | -7.90% | -6.66% | -1.90% |
Free Cash Flow Margin | -8.60% | -4.04% | 4.22% | 4.24% | -1.15% | -7.45% |
EBITDA | -51.51 | -37.89 | 43.82 | 33.58 | 45.23 | 166.83 |
EBITDA Margin | -7.26% | -3.52% | 2.42% | 1.67% | 1.96% | 6.42% |
D&A For EBITDA | 20.47 | 27.19 | 36.15 | 52.5 | 60.74 | 72.01 |
EBIT | -71.98 | -65.08 | 7.66 | -18.91 | -15.51 | 94.81 |
EBIT Margin | -10.15% | -6.04% | 0.42% | -0.94% | -0.67% | 3.65% |
Revenue as Reported | 219.75 | 1,077 | 1,811 | 2,006 | 2,309 | 2,600 |
Advertising Expenses | - | - | - | - | - | 12.89 |